Cytomegalovirus (CMV): Epidemiology Forecast to 2027

Cytomegalovirus (CMV) is a common virus belonging to the Herpesviridae family. CMV is present in up to 60% of adults in high-income countries and up to 100% of adults in low- and middle-income countries. In individuals with healthy immune systems, CMV infections are typically asymptomatic, and the virus establishes a lifelong latent infection. Certain populations, such as people living with human immunodeficiency virus (HIV), solid organ transplant (SOT) patients, allogeneic hematopoietic stem cell transplant (allo-HSCT) patients, and infants infected in utero, are vulnerable to symptomatic disease caused by primary CMV infections or reactivation. CMV disease may also occur in critically ill immunocompetent patients. Depending on the population, CMV disease can present as end-organ disease (infection and symptoms in lung, gastrointestinal (GI) tract, liver, retina, or other organs), CMV syndrome (fever, fatigue, leukopenia, and/or thrombocytosis), or congenital CMV (cCMV) (symptoms ranging from mild manifestations to premature birth and neurologic sequelae).

This forecast is strengthened by a thorough review of historical data and current literature on CMV disease in the 7MM. In addition, the use of consistent methodology for calculation of CMV cases allows for meaningful comparisons between markets. This analysis also provides detailed segmentation of CMV disease by age, sex, and population at risk. Additional segmentations on disease manifestation, transplant patient serostatus, and seroprevalence in pregnant women and the general population can be found in the GlobalData Cytomegalovirus (CMV) Epidemiology Forecast Model.

The following data describes epidemiology of CMV cases. In 2017, there were 9,691 diagnosed incident cases of CMV disease in the 7MM. The US had the most cases (5,885), while Japan had the fewest (271). GlobalData epidemiologists forecast that the number of CMV cases in the 7MM will increase to 10,704 in 2027, at an Annual Growth Rate (AGR) of 1.05%. All countries besides Germany are expected to see an increase in CMV cases. HIV patients made up the greatest burden of CMV cases in the 7MM in 2017 (3,734 cases), followed closely by SOT patients (3,696 cases). cCMV accounted for the fewest cases (979).

Scope

The Cytomegalovirus (CMV) Epidemiology Forecast Report and Epidemiology Forecast Model provide an overview of the risk factors and global trends of CMV in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

This report provides an overview of the risk factors, comorbidities, and global and historical trends for CMV disease among HIV, SOT, allo-HSCT, and newborn populations in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for diagnosed incident cases of CMV disease segmented by population at risk, sex, and age (in 10-year age groups beginning at ages 0–10 years and ending at ages 80 years and older) in these markets. In addition, this report includes a 10-year forecast for SOT and allo-HSCT patient populations in the 7MM.

The CMV epidemiology forecast report and model were written and developed by Masters- and PhD-level epidemiologists.

The Epidemiology Forecast Report is in-depth, high quality, transparent, and market-driven, providing expert analysis of disease trends in the 7MM.

The Epidemiology Forecast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The CMV Epidemiology Forecast series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global CMV market.

Quantify patient populations in the global CMV market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CMV therapeutics in each of the markets covered.

Understand magnitude of CMV population by population at risk.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 CMV: Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 ...

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 CMV: Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.3.1 CMV Disease in Diagnosed Prevalent HIV Patients

3.3.2 CMV Disease in SOT Patients

3.3.3 CMV Disease in Allo-HSCT Patients

3.3.4 Congenital CMV Disease

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods

3.5 Epidemiological Forecast for CMV (2017–2027)

3.5.1 Diagnosed Incident Cases of CMV

3.5.2 Age-Specific Incident Cases of CMV

3.5.3 Sex-Specific Diagnosed Incident Cases of CMV

3.5.4 CMV Diagnosed Incident Cases by Population at Risk

3.5.5 HIV-CMV

3.5.6 SOT Patients

3.5.7 SOT-CMV

3.5.8 HSCT Patients

3.5.9 HSCT-CMV

3.5.10 Diagnosed Incident Cases of Congenital CMV

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 Limitations of Analysis

3.6.3 Strengths of Analysis

4 Appendix

4.1 Bibliography

4.2 About the Authors

4.2.1 Epidemiologist

4.2.2 Reviewers

4.2.3 Global Director of Therapy Analysis and Epidemiology

4.2.4 Global Head and EVP of Healthcare Operations and Strategy

4.3 About GlobalData

4.4 Contact Us

4.5 Disclaimer

List of Tables

Table 1: Risk Factors and Comorbidities for CMV

Table 1: Risk Factors and Comorbidities for CMV

List of Figures

Figure 1: 7MM, Diagnosed Incident Cases of CMV, Both Sexes, All Ages, 2017 and 2027

Figure 2: Age-Standardized Diagnosed Incidence of CMV Disease, All Ages, ...

Figure 1: 7MM, Diagnosed Incident Cases of CMV, Both Sexes, All Ages, 2017 and 2027

Figure 2: Age-Standardized Diagnosed Incidence of CMV Disease, All Ages, 2017

Figure 3: Case Flow Map

Figure 4: Sources Used and Not Used for Calculations of Diagnosed Incident Cases of HIV-CMV

Figure 5: Sources Used and Not Used for Calculations of SOT Patients

Figure 6: Sources Used and Not Used for Calculations of Diagnosed Incident Cases of SOT-CMV

Figure 7: Sources Used and Not Used for Calculations of Allo-HSCT Patients and Diagnosed Incident Cases of HSCT-CMV

Figure 8: Sources Used and Not Used for Calculations of Live Births and cCMV Cases

Figure 9: Diagnosed Incident Cases of CMV, 7MM, Men and Women, All Ages, 2017

Figure 10: 7MM, Age-Specific Diagnosed Incident Cases of CMV Disease, Men and Women, 2017

Figure 11: 7MM, Sex-Specific Diagnosed Incident Cases of CMV Disease, All Ages, 2017

Figure 12: 7MM, Diagnosed Incident Cases of CMV Disease by Population at Risk, Men and Women, All Ages, 2017

Figure 13: 5EU and Japan, Diagnosed Incident Cases of HIV-CMV, Men and Women, All Ages, 2017–2027

Figure 14: US, Diagnosed Incident Cases of HIV-CMV, Men and Women, All Ages, 2017–2027

Figure 15: 7MM, SOT Patients, Men and Women, All Ages, 2017–2027

Figure 16: 7MM, Diagnosed Incident Cases of SOT-CMV, Men and Women, All Ages, 2017–2027

Figure 17: 7MM, Allo-HSCT Patients, Men and Women, All Ages, 2017–2027

Figure 18: 7MM, Diagnosed Incident Cases of HSCT-CMV, Men and Women, All Ages, 2017–2027

Figure 19: 5EU and Japan, Diagnosed Incident Cases of cCMV, Men and Women, All Ages, 2017–2027

Figure 20: US, Diagnosed Incident Cases of cCMV, Men and Women, All Ages, 2017–2027

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports